NRX Pharmaceuticals has signed an important deal with DARPA for a clinical trial worth about $11.2 million.

Oct 5, 2026, 5:08 PM ETDealRead the original at SEC EDGAR

Good for NRXP

NRX Pharmaceuticals won a DARPA contract worth about $11.2 million for a depression study, supporting its treatment program. Only $6.7 million is committed so far, and later funding depends on government approvals and options.

NRXP · NRX Pharmaceuticals, Inc.

AI read · Good for NRXP

The AI's read

The award gives NRX funding for a study of its depression treatment and brings the work closer to testing in patients. The FDA has approved the trial, and patient enrollment is expected to begin. Only $6.7 million is committed so far. Later funding depends on government appropriations and options, payments depend on accepted milestones, and either side can end the contract in certain cases. The award still supports NRX's work despite those limits.

Get alerts for NRXP

Follow NRX Pharmaceuticals, Inc. (NRXP) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for NRXP

Free on the App Store and Google Play, or on the web.